These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 30377816)

  • 21. Optimal retreatment schedule of rituximab for neuromyelitis optica spectrum disorder: A systematic review.
    Abbadessa G; Miele G; Maida E; Minervini G; Lavorgna L; Bonavita S
    Mult Scler Relat Disord; 2022 Jul; 63():103926. PubMed ID: 35661568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success.
    Greenberg BM; Graves D; Remington G; Hardeman P; Mann M; Karandikar N; Stuve O; Monson N; Frohman E
    Mult Scler; 2012 Jul; 18(7):1022-6. PubMed ID: 22261118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica.
    Yang CS; Yang L; Li T; Zhang DQ; Jin WN; Li MS; Su N; Zhangning N; Liu Q; Shao ZH; Yu C; Shi FD
    Neurology; 2013 Aug; 81(8):710-3. PubMed ID: 23884041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EBI2-expressing B cells in neuromyelitis optica spectrum disorder with AQP4-IgG: Association with acute attacks and serum cytokines.
    Baek SH; Kim B; Shin JY; Choi SJ; Ahn SH; Choi YS; Kim SM; Sung JJ
    J Neuroimmunol; 2021 Sep; 358():577637. PubMed ID: 34229205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.
    Bennett JL; Aktas O; Rees WA; Smith MA; Gunsior M; Yan L; She D; Cimbora D; Pittock SJ; Weinshenker BG; Paul F; Marignier R; Wingerchuk D; Cutter G; Green A; Hartung HP; Kim HJ; Fujihara K; Levy M; Katz E; Cree BAC;
    EBioMedicine; 2022 Dec; 86():104321. PubMed ID: 36370634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration.
    Tahara M; Oeda T; Okada K; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
    Mult Scler Relat Disord; 2022 Apr; 60():103730. PubMed ID: 35287025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders.
    Fragomeni MO; Bichuetti DB; Oliveira EML
    Mult Scler Relat Disord; 2018 Oct; 25():138-142. PubMed ID: 30075406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphocyte Subsets Are Associated with Disease Status in Neuromyelitis Optica Spectrum Disorders.
    Yang H; Liu W; Wu YF; Zhu DS; Shen XF; Guan YT
    Neuroimmunomodulation; 2022; 29(4):296-305. PubMed ID: 34903694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report.
    He D; Yu Y; Yan W; Dai Q; Xu Z; Chu L
    Pediatr Neurol; 2014 Aug; 51(2):255-8. PubMed ID: 25079575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city.
    Ashtari F; Mehdipour R; Shaygannejad V; Mansourian M
    Mult Scler Relat Disord; 2019 Sep; 34():77-82. PubMed ID: 31233958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.
    Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W
    J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
    Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
    Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders.
    Lim YM; Kim H; Lee EJ; Kim HW; Kim HJ; Kim KK
    Mult Scler Relat Disord; 2020 Jul; 42():102109. PubMed ID: 32387973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients.
    Radaelli M; Moiola L; Sangalli F; Esposito F; Barcella V; Ferrè L; Rodegher M; Colombo B; Fazio R; Martinelli V; Comi G
    Mult Scler; 2016 Apr; 22(4):511-9. PubMed ID: 26199350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease.
    Magaña SM; Pittock SJ; Lennon VA; Keegan BM; Weinshenker BG; Lucchinetti CF
    Arch Neurol; 2009 Aug; 66(8):964-6. PubMed ID: 19667216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region.
    Dale GH; Svendsen KB; Gjelstrup MC; Christensen T; Houen G; Nielsen E; Bek T; Petersen T
    Acta Neurol Scand; 2018 Jun; 137(6):582-588. PubMed ID: 29359475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficiency of antibody therapy in demyelinating diseases.
    Akaishi T; Nakashima I
    Int Immunol; 2017 Jul; 29(7):327-335. PubMed ID: 28910968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab regimen for NMOSD: A real-world case series study.
    Cao S; Wang X; Ji X; Tian J; Zhu Y; Wang X; Gu Y; Duan X; Xiao X; Fang Q; Zhang X; Xue Q
    Mult Scler Relat Disord; 2023 Feb; 70():104524. PubMed ID: 36701910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study.
    Cabre P; Mejdoubi M; Jeannin S; Merle H; Plumelle Y; Cavillon G; Smadja D; Marignier R;
    J Neurol; 2018 Apr; 265(4):917-925. PubMed ID: 29455361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.